CTRI/2023/10/058571已完成3 期
A Phase III, Prospective, Randomized, Double Blind, Active-Controlled, Comparative, Parallel Group, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Bilastine 40 mg plus Montelukast 10 mg Tablets Versus Fixed Dose Combination of Bilastine 20 mg plus Montelukast 10 mg Tablets in Adult Patients with Severe Allergic Rhinitis. ? - NI
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients aged between 18 and 65 years (both inclusive).
- •2. Patients with a history of allergic rhinitis, a positive skin prick test or radio allegro sorbent test (RAST) to at least one relevant allergen and active symptoms of allergic rhinitis at screening or baseline visit.
- •3. Patients with visual analogue scale (VAS) score of 5 or more for total nasal symptoms and/or severe ocular symptoms at screening or baseline visit.
- •4. Women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study. WOCBP must have a negative urine pregnancy test at screening / baseline visit.
- •5. Patients with ability to understand and provide written, dated and signed informed consent form, which must have been obtained prior to screening.
- •6. Patients willing to comply with all the protocol requirements.
排除标准
- •1. Patients with hypersensitivity to either of the study medications or any of the ingredients of the formulation.
- •2. Patients with electrocardiographic abnormalities including conduction delay and an abnormal QTc interval.
- •3. Patients with upper respiratory tract infections including cold and systemic infections within 3 weeks of baseline or screening visit.
- •4. Patients with history of renal, hepatic, gastrointestinal tract, cardiovascular, respiratory, haematological, endocrine or neurological diseases.
- •5. Patients with clinically significant impaired hepatic function (SGOT and SGPT more than 2.5X the UNL) or renal dysfunction (serum creatinine = 2.5 mg/dL).
- •6. Patients who had initiation of allergen immunotherapy within previous 6 months.
- •7. Patients with history of rhinitis medicamentosa, non-allergic rhinitis or substantial structural nasal obstruction.
- •8. Patients with history of nasal polyps or any clinically important nasal anomaly.
- •9. Patients with history of acute and/or chronic sinusitis within 30 days of baseline or screening visit.
- •10. Patients with history of eye surgery or intranasal surgery within 3 months of baseline or screening visit.
- •11. Patient with severe asthma requiring emergency room treatment within 1 month or hospitalization within 3 months before the trial.
- •12. Female patients who are pregnant or breast-feeding or expecting to conceive within the projected duration of the study.
- •13. Female patients who are of childbearing potential and who are neither surgically sterilized nor willing to use reliable contraceptive methods (like hormonal, barrier methods or intrauterine device).
- •14. Patients with uncontrolled hypertension with sitting systolic BP = 160 mmHg and/or diastolic BP = 100 mmHg at screening.
- •15. Patients with a history of any malignancy.
- •16. Patients with known case of infection with hepatitis B, hepatitis C or HIV.
- •17. Patients with concurrent participation in another clinical trial or any investigational therapy within 30 days prior to screening visit.
- •18. Patients currently taking prohibited medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
- •19. Suspected inability or unwillingness to comply with the study procedures.
- •20. Patients with any condition which, in the judgment of the Investigator, may render the patient unable to complete the study or which may pose a significant risk to the patient.
研究者
相似试验
已完成
3 期
A clinical study to assess the efficacy and safety of Tedizolid Tablets for the treatment of bacterial skin infections.CTRI/2023/12/060921Exemed Pharmaceuticals243
已完成
3 期
A clinical trial to study the effect of Topiroxostat Tablets in Patients with high uric acid levels in the blood.CTRI/2021/02/031284Precise Biopharma P Limited188
已完成
3 期
A study to examine the effect of Medroxyprogesterone Acetate Sustained Release Tablets 30 mg for the treatment of endometriosis associated pain in women.CTRI/2020/10/028464Synokem Pharmaceuticals Ltd186
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Linagliptin plus Dapagliflozin Tablets in Patients with Type 2 Diabetes Mellitus not Controlled on Metformin.CTRI/2023/02/049931Synokem Pharmaceuticals Ltd.
已完成
3 期
A clinical study to assess the efficacy and safety of Imeglimin SR Tablets 1000 mg in patients with diabetes.CTRI/2022/12/048611Exemed Pharmaceuticals216